Sanofi-aventis and Metabolex
enter into an Exclusive Worldwide
Licensing Agreement for a Novel Oral
to treat Type II Diabetes
- New oral agent has a dual mechanism of action affecting both insulin
and GLP-1 release -
Paris, France – June 25, 2010 – Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and Metabolex announced
today a global licensing agreement on MBX-2982, an oral agent, GPR119 receptor agonist, for the treatment of Type II
Diabetes. GPR119 receptor agonists (or G-protein coupled receptor 119) are found to exert the effects on glucose
metabolism by a dual mode of action affecting both insulin and GLP-1 (glucagon-like peptide-1) release. This
innovative mechanism could offer improved glucose control over the existing oral diabetes therapies, with an additional
potentially beneficial effect on weight.
Under this agreement, sanofi-aventis will receive an exclusive worldwide license to develop, manufacture and
commercialize MBX-2982, currently in Phase II a, and related compounds.
“The new mechanism of action of MBX-2982 is very promising and we are excited to have identified Metabolex as our
partner in this very competitive field ”, declared Pierre Chancel, Senior Vice-President, Global Diabetes, sanofi-
aventis. “With the growing epidemic of type II diabetes, more effective and well tolerated oral treatment options
continue to be a cornerstone of innovative treatment schemes. In this sense, this agreement is another important
step for sanofi-aventis towards our ambition to provide integrated solutions for diabetic patients”.
Under the terms of the agreement, Metabolex will receive an upfront payment and will be eligible to receive
development, regulatory, and specified commercial milestone payments. The total of all those payments could reach
US$ 375 million. Metabolex will also receive royalties on the worldwide product sales.
The license agreement is subject to antitrust clearance in the United States under the Hart-Scott-Rodino Act.